treatment
KEYNOTE-483: Keytruda Combo Approved
KEYNOTE-483 Phase 3 trial shows pembrolizumab plus chemotherapy improves survival to 17.3 months. FDA approved September 2024 for first-line treatment.
2024 News Archive
9 articles
September 2024
clinical-trials
FDA Approves Keytruda Combo for Mesothelioma
The FDA approved pembrolizumab (Keytruda) with chemotherapy for advanced pleural mesothelioma, showing a 21% reduction in death risk in the KEYNOTE-483 trial.
news
9/11 Mesothelioma Crisis Still Unfolding
Mesothelioma develops 20 to 50 years after asbestos exposure, so the cases tied to 9/11 are only starting to appear. Here's what the data shows so far.
July 2024
research
DENIM Trial: Vaccine Did Not Extend Survival
The Phase 2/3 DENIM trial found that dendritic cell vaccination did not extend overall survival for people with mesothelioma after chemotherapy.
exposure
WHO Classifies Talc as Probable Carcinogen
IARC upgrades talc to Group 2A carcinogen in July 2024 based on ovarian cancer links and asbestos contamination concerns.
May 2024
research
MARS 2: Chemo Outperformed Surgery
The landmark MARS 2 trial found that chemotherapy alone led to better survival than surgery plus chemotherapy for people with pleural mesothelioma.
March 2024
exposure
EPA Bans Chrysotile: First U.S. Asbestos Ban
EPA bans chrysotile asbestos in March 2024 under TSCA. Phase-out periods of 5–12 years for remaining industrial uses.
February 2024
treatment
ATOMIC-Meso: Quadrupled 3-Year Survival
The ATOMIC-Meso trial showed pegargiminase plus chemotherapy quadrupled 3-year survival rates in nonepithelioid mesothelioma, the most aggressive subtype.
January 2024
treatment
CONFIRM Trial: Nivolumab Extends Survival in Relapsed Mesothelioma
CONFIRM (Phase 3, 332 patients) showed nivolumab improved median OS to 10.2 vs 6.9 months in relapsed mesothelioma. PD-L1 did not predict benefit.